ArticleRevista medica del Instituto Mexicano del Seguro Social2022
[The estimated economic impact of cardiovascular and diabetes mellitus complications 2019-2028].
Article in Revista medica del Instituto Mexicano del Seguro Social, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 3 citations in OpenAlex.
- [Biophysical and biochemical differences in CADIMSS patients: Different therapeutic managements].Revista medica del Instituto Mexicano del Seguro Social · 2026Article
- Knowledge level on prediabetes of family physicians and family medicine resident physicians.Journal of family medicine and primary care · 2026Article
- Serum asprosin, ox-LDL, and LOX-1 levels in patients with hypertension and their association with cardiovascular risk.Biomarkers in medicine · 2025Article
- Comprehensive study of associated factors with Type 2 Diabetes in Mexico: protocol.Revista medica del Instituto Mexicano del Seguro Social · 2025Observational
- Estimation of the Burden of Disease Due to Diabetes Mellitus Type 2 in the Population of Tabasco During the Period 2013-2023.International journal of environmental research and public health · 2025Observational
- Mortality and Years of Life Lost From Cardiometabolic Diseases in Mexico: National and State-Level Trends, 1998-2022.Public health reports (Washington, D.C. : 1974)Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In Mexico, diabetes mellitus (DM) and diseases cardiovascular, register an upward trend. Objective: To estimate the number of complications due to cardiovascular events (CVD) and complications derived from DM (CDM) accumulated in beneficiaries of the Mexican Institute of Social Security (IMSS) from 2019 to 2028, as well as the expense for medical and economic benefits in a scenario baseline and one of change in metabolic profile due to lack of medical follow-up during the COVID-19 pandemic. Material and methods: The number of CVD and CDM was estimated from 2019, with a 10-year risk projection using the ESC CVD Risk Calculator and United Kingdom Prospective Diabetes Study, considering risk factors registered in the institutional databases. Results: From 2019 to 2028, cumulative CVD cases were estimated at 2 million and those of CDM in 960 thousand, with an impact on medical spending of 439,523 million pesos and on the economic benefits of 174,085 millions. When considering the COVID-19 pandemic, CVD events and CDM increased by 589 thousand, with an increase in spending of 93,787 million pesos for medical care and 41,159 million for economic benefits. Conclusions: Without a comprehensive intervention in the management of CVD and CDM, the cost by both diseases will continue to increase, with financial pressures getting older.
Indexed as
Identifiers
36795992PMC10629407W4321172350What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.